These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 17180765)

  • 1. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 2. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 3. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 5. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 6. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 8. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 9. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 10. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 11. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 13. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 15. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 18. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 19. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 20. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.